Technology Appraisal Committee Meeting (Committee C)

### Minutes: [Unconfirmed]

### Date: [Wednesday 7th October]

## Present:

### Stephen O’Brien, Chair Present for all notes

* Alex Cale Present for all notes
* Michael Chambers Present for all notes
* Prithwiraj Das Present for all notes
* David Foreman Present for all notes
* Rob Forsyth Present for all notes
* Natalie Hallas Present for all notes
* John Hampson Present for all notes
* Nigel Langford Present for all notes
* Andrea Manca Present for all notes
* Kirandip Moyo Present for all notes
* Mudasa Mushtaq Present for all notes
* Richard Nicholas Present for all notes
* Ugochi Nwulu Present for all notes
* Stella O’Brien Present for all notes
* Subhash Pokhel Present for all notes
* Andrew Renehan Present for all notes
* Peter Selby Present for all notes
* Paul Tappenden Present for all notes
* Derek Ward Present for all notes

### In attendance:

* Jasdeep Hare, Associate Director, NICE, Present for all notes
* Gavin Kenny, Project Manager, NICE, Present for all notes
* Isamhan Abudullah , Administrator, NICE, Present for all notes
* Jamie Elvidge, Technical Analyst, NICE, Present for all notes
* Luke Cowie, Technical Adviser, NICE, Present for all notes
* Sophie McHugh, Administrator, NICE, Present for all notes
* Mandy Bereton, Assistant Project Manager, Present for all notes
* Louise Jafferally, Project Manager, NICE, Present for all notes
* Matt Stevenson, ScHARR, Evidence Review Group, Present for notes 1 to 6
* John Stevens, , ScHARR, Evidence Review Group, Present for notes 1 to 6
* Andrew Metry, , ScHARR, Evidence Review Group, Present for notes 1 to 6
* Prof Tim Meyer, Clinical Expert, Present for notes 1 to 6
* Dr Paul Ross, Clinical Expert, Present for notes 1 to 6
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 1 to 6

### Non-public attendees:

* Sean Gill, NIHRIO, Present for all notes
* Ella Livingstone, NICE Observor, Present for all notes
* Kusal Lokuge, NICE Observor, Present for all notes
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for all notes
* Catherine Pank, Public Involvement adviser, NICE, Present for notes 1 to 6
* Catherine Richmond, NIHRIO, Present for all notes
* Natalie Spray, NICE Observor, Present for all notes
* Ria Skeleton, NICE Observor, Present for all notes
* Philip Williams, NICE Observor, Present for all notes

### Notes

### Any other Business

1. none

### Appraisal of ID1655 - Atezolizumab with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Roche Products.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

3.1 Michael Chambers declared a non-personal specific financial interest as he is helping to run a training programme on Real World Evidence, co-ordinated by the University of Utrecht, for Roche Pharmaceuticals. This did not involve consideration of any Roche products.

* + 1. It was agreed that this declaration would not prevent Michael from participating in this section of the meeting.

3.2 Richard Nicholas declared a personal specific financial interest as he has previously been an investigator for Roche in trials and attended advisory in multiple sclerosis using ocrelizumab.

3.2.1 It was agreed that this declaration would prevent Richard from participating in this section of the meeting.

3.3 Prithwiraj Das declared a non-financial and personal interest as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Thrombolysis) in the UK & Ireland. Prithwiraj noted that BI may have various early-phase molecules in the pipeline, he also confirmed he has not worked on any of the indications under investigation in the last 12 months.

3.3.1. It was agreed that this declaration would not prevent Prithwiraj from participating on this topic.

3.4 Paul Tappenden declared a personal specific financial interest as he provided an internal peer review of the draft ERG report

3.4.1 It was agreed that this declaration would prevent Paul from participating in this section of the meeting.

3.5 Tim Mayer declared conflicts of interest as he has sat on advisory boards for Roche, AstraZeneca, Eisai, BTG and Ipsen and has recruited to multiple commercially sponsored trials in HCC including the trial in which the drugs in question have been evaluated, he was involved with IMBRAVE150 trail and worked on the advisory board for Roche

3.5.1 It was agreed that this declaration would not prevent Tim from participating in part 1 discussions on this topic.

3.6 Paul Ross declared a conflicts of interest as he has reveived the following;

* Roche – fee for speaking and support for attending ESMO conference 2019
* Bayer – support for attending ASCO 2019
* Bayer – Educational grant to support work for submission to GI ASCO 2020 and travel support for the same meeting
* Eisai – speaker fee First Thoughts, HCC CNS Forum 2020 and fee for advisory board
* Servier – speaker fee
* Pierre Fabre – fee for Advisory Board
* Sanofi (ongoing research funding)
* Sirtex – Fee for advisory board
* Amgen – speaker fee

Paul also confirmed he was involved with IMBRAVE150 trail and worked on the advisory board for Roche

3.6.1 It was agreed that this declaration would not prevent Paul from participating in this section of the meeting.

4. No further conflicts of interest were declared for this appraisal.

5. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.

6. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)**

7. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.

8. The committee decision was based on consensus.

9. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.